193 related articles for article (PubMed ID: 15304981)
1. Design and evaluation of cyclodextrin-based drug formulation.
Uekama K
Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):900-15. PubMed ID: 15304981
[TBL] [Abstract][Full Text] [Related]
2. [Pharmaceutical application of cyclodextrins as multi-functional drug carriers].
Uekama K
Yakugaku Zasshi; 2004 Dec; 124(12):909-35. PubMed ID: 15577263
[TBL] [Abstract][Full Text] [Related]
3. [Novel approach of cyclodextrin-based pharmaceutical formulation].
Uekama K
Yakugaku Zasshi; 2012; 132(1):85-105. PubMed ID: 22214584
[TBL] [Abstract][Full Text] [Related]
4. [Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers].
Hirayama F
Yakugaku Zasshi; 1993 Jun; 113(6):425-37. PubMed ID: 8355145
[TBL] [Abstract][Full Text] [Related]
5. Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta-cyclodextrin derivatives and formulation as oleaginous suppository.
Arima H; Kondo T; Irie T; Uekama K
J Pharm Sci; 1992 Nov; 81(11):1119-25. PubMed ID: 1447717
[TBL] [Abstract][Full Text] [Related]
6. Unique structure and property of cyclodextrins and their application in transdermal drug delivery.
Hu J; Tao Z; Cao S
Methods Find Exp Clin Pharmacol; 2009 Sep; 31(7):449-56. PubMed ID: 19907720
[TBL] [Abstract][Full Text] [Related]
7. Cyclodextrin-based controlled drug release system.
Hirayama F; Uekama K
Adv Drug Deliv Rev; 1999 Mar; 36(1):125-141. PubMed ID: 10837712
[TBL] [Abstract][Full Text] [Related]
8. Release characteristics of endogenous constituents by exposure of small intestine to modified beta-cyclodextrins.
Tanino T; Ogiso T; Iwaki M; Yamaguchi T; Kakehi K
Biol Pharm Bull; 1999 Oct; 22(10):1099-105. PubMed ID: 10549863
[TBL] [Abstract][Full Text] [Related]
9. Potential Use of Cyclodextrins as Drug Carriers and Active Pharmaceutical Ingredients.
Arima H; Motoyama K; Higashi T
Chem Pharm Bull (Tokyo); 2017; 65(4):341-348. PubMed ID: 28381674
[TBL] [Abstract][Full Text] [Related]
10. Cyclodextrins in topical drug formulations: theory and practice.
Loftsson T; Masson M
Int J Pharm; 2001 Aug; 225(1-2):15-30. PubMed ID: 11489551
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in cyclodextrin delivery techniques.
Arima H; Hayashi Y; Higashi T; Motoyama K
Expert Opin Drug Deliv; 2015; 12(9):1425-41. PubMed ID: 26098975
[TBL] [Abstract][Full Text] [Related]
12. Cyclodextrins in drug delivery.
Loftsson T; Jarho P; Másson M; Järvinen T
Expert Opin Drug Deliv; 2005 Mar; 2(2):335-51. PubMed ID: 16296758
[TBL] [Abstract][Full Text] [Related]
13. Polypseudorotaxanes of pegylated insulin with cyclodextrins: application to sustained release system.
Higashi T; Hirayama F; Arima H; Uekama K
Bioorg Med Chem Lett; 2007 Apr; 17(7):1871-4. PubMed ID: 17291751
[TBL] [Abstract][Full Text] [Related]
14. Ester-Based Hydrophilic Cyclodextrin Nanosponges for Topical Ocular Drug Delivery.
Hayiyana Z; Choonara YE; Makgotloe A; du Toit LC; Kumar P; Pillay V
Curr Pharm Des; 2016; 22(46):6988-6997. PubMed ID: 27981908
[TBL] [Abstract][Full Text] [Related]
15. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
Mady FM; Farghaly Aly U
Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
[TBL] [Abstract][Full Text] [Related]
16. Improvement of some physicochemical properties of arundic acid, (R)-(-)-2-propyloctanonic acid, by complexation with hydrophilic cyclodextrins.
Miyamoto Y; Nakahara M; Motoyama K; Ishiguro T; Oda Y; Yamanoi T; Okamoto I; Yagi A; Nishimura H; Hirayama F; Uekama K; Arima H
Int J Pharm; 2011 Jul; 413(1-2):63-72. PubMed ID: 21540089
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical properties of inclusion complexes of highly soluble β-cyclodextrins with highly hydrophobic testosterone propionate.
Celia C; Scala A; Stancanelli R; Surdo E; Paolino D; Grattoni A; Micale N; Crupi V; Majolino D; Fresta M; Tommasini S; Venuti V; Ventura CA
Int J Pharm; 2017 Dec; 534(1-2):316-324. PubMed ID: 29042336
[TBL] [Abstract][Full Text] [Related]
18. Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin.
Abe K; Irie T; Uekama K
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2232-7. PubMed ID: 8582025
[TBL] [Abstract][Full Text] [Related]
19. Peracylated beta-cyclodextrins as novel sustained-release carriers for a water-soluble drug, molsidomine.
Uekama K; Horikawa T; Yamanaka M; Hirayama F
J Pharm Pharmacol; 1994 Sep; 46(9):714-7. PubMed ID: 7837039
[TBL] [Abstract][Full Text] [Related]
20. Potential use of polypseudorotaxanes of pegylated polyamidoamine dendrimer with cyclodextrins as novel sustained release systems for DNA.
Motoyama K; Hayashida K; Arima H
Chem Pharm Bull (Tokyo); 2011; 59(4):476-9. PubMed ID: 21467677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
